Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Sponsor: Bayer

The FINEARTS-HF aims to evaluate the effects of finerenone versus a placebo in reducing cardiovascular death and heart failure events in patients with heart failure and an ejection fraction of 40% or higher. It will also assess the impact on patients’ lives, changes in kidney function, and the tolerability of finerenone. The study will include 6,000 patients with HF who will take an oral tablet of the study product for up to 43 months.

The study is closed for patient recruitment.

Study Team:
SI: drs. B.J. van Essen
Project coordinator: G.H. de Jong

People involved

Principal investigator

Adriaan Voors